Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Slides:

Advertisements

Similar presentations

Candidate Vaccine Strains and Potency Reagents for Influenza Season

Advertisements

Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.

INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA (Seasonal Influenza and Zoonotic Influenza) FEBRUARY 28, 2012.

Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

CAF01 adjuvant increases the protection conferred by a commercially available influenza split vaccine in a ferret model Introduction Desirable traits of.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

INFLUENZA VACCINE Group 1 Zainab Ashfaq Bushra Abbas Ahtasham Danish.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.

NS 2 Lipid Bilayer NA (Neuraminidase) HA (Hemagglutinin) M 2 (Ion channel) M 1 (Matrix protein) NP (Nucleocapsid) PB1, PB2, PA (Transcriptase complex)

INTRODUCTION TO INFLUENZA The (Ferret) Sneeze Heard Around The World: The Case Of The Bioengineered Bird Flu Case Study for AAC&U STIRS Project Jill M.

INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA FEBRUARY 22, 2010 Nancy J. Cox, Ph. D Director WHO COLLABORATING.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

Vaccines and Related Biological Products Advisory Committee Presentation on Sanofi Pasteur’s H5N1 Vaccine Andrea N. James, M.D. Senior Medical Officer.

Martha Thompson, MPH Viral Isolation Team Leader Medical Virology Group Laboratory Services Section TX DSHS Influenza Surveillance Viral Isolation Laboratory.

Update on Influenza A(H5N1) Activity in Asia Nancy J. Cox, Ph.D. Chief, Influenza Branch National Center for Infectious Diseases Centers for Disease Control.

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

Influenza Vaccine Manufacturing Industry Perspective Tony Colegate Novartis Vaccines and Diagnostics Prepared by PhRMA Vaccine Technical Committee for.

VRBPAC 25 February 2011 Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

Influenza Update September 2015

Review and Discussion Time line courtesy of:

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

Update on Pandemic Vaccine Development 3 rd WHO WPRO/SEARO NIC Meeting August, 2009, Beijing Masato Tashiro, MD., PhD. Director, WHO Collaborating.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Vaccines and Related Biological Products Advisory Committee Meeting July 23, 2009 Pandemic Influenza A (H1N1) Virology Update Nancy Cox, PhD Alexander.

Options for Influenza Vaccine Composition Summary of Data Options with Pros and Cons.

FDA/CBER Vaccines and Related biological Products Advisory Committee Meeting Discussion of Clinical Trials to Support use of Vaccines against the 2009.

Ian Barr WHO Collaborating Centre for Reference & Research on Influenza, Melbourne (Now finally re-located at VIDRL) Influenza surveillance in Australia,

INFLUENZA UPDATE DEBBYE ROSEN ADULT IMMUNIZATION COORDINATOR CONNECTICUT DEPARTMENT OF PUBLIC HEALTH

Update on Influenza Virus Surveillance Findings in 2008/09 Season in Northern Hemisphere Who Collaborating Center for Reference and Research on Influenza.

Influenza Virus Vaccine Composition Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products.

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER Regulatory Approaches & Activities To Support Licensure of Pandemic (H1N1) 2009 Vaccine.

Samar Musmar,MD,FAAFP Vice Dean for Clinical Affairs An-Najah National University Faculty of Medicine Head, Medicine and Society Dep. Flu Vaccination in.

Influenza Activity and Virus Characterizations (Northern Hemisphere) 5thMeeting of NICs in the WPR and SEAR 7-10 June, 2011 Laos Takato Odagiri WHO Collaborating.

Influenza Branch VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA February 16-17, 2005, Bethesda, MD Nancy COX, Ph.D. WHO COLLABORATING.

Update on Surveillance for Influenza Viruses with Pandemic Potential and Candidate Vaccine Viruses Nancy Cox, PhD CDC.

1 Influenza activity in the Southern Hemisphere Ian Barr WHO CC for Reference & Research on Influenza Melbourne The Melbourne WHO.

RCGP England: ‘influenza and influenza-like illness’

Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/22/2010) Jerry P. Weir, Ph.D., Director.

1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.

“Neutralizing Antibodies Derived from the B Cells of 1918 Influenza Pandemic Survivors” (Yu et. al) Daniel Greenberg.

Novartis Vaccines - Influenza A H1N1v vaccine development Theodore F Tsai MD MPH July 23, 2009 DHHS supported influenza cell culture vaccine production.

Lisa Grohskopf, MD, MPH U.S. Influenza Surveillance Season National Center for Immunization & Respiratory Diseases Influenza Division U.S. Food.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Options for Influenza Vaccine Composition Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological.

STATUS OF CANDIDATE VACCINE STRAINS AND POTENCY REAGENTS Zhiping Ye, M.D., Ph.D. FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH.

INFORMATION FOR THE VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE, CEBR, FDA February 27-28, 2007 WHO COLLABORATING CENTER FOR SURVEILLANCE,

Marketing Authorisation & Yearly Licence of Influenza Vaccines - „Mock-up” & Pre-Pandemic Influenza Vaccines Zsuzsanna Pauliny MD

Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Impact of Influenza Vaccination on Seasonal Mortality.

1 Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine After Priming With an.

Influenza Virologic Surveillance and Vaccine Strain Selection Xiyan Xu MD Deputy Director WHO Collaborating Center for Surveillance, Epidemiology and Control.

The State of Communicable Diseases in Indiana

ACIP Recommendations Update for the U.S. Influenza Season

Copyright © 2014 American Medical Association. All rights reserved.

U.S. Food and Drug Administration

CD154 Expression Is Associated with Neutralizing Antibody Titer Levels Postinfluenza Vaccination in Stem Cell Transplant Patients and Healthy Adults

M. Koopmans, E. de Bruin, G. -J. Godeke, I. Friesema, R

Breadth of binding and HAI activity of serum Ab from i. n. + i. p

J. -H. Lin, S. -C. Chiu, J. -C. Cheng, H. -W. Chang, K. -L. Hsiao, Y

Presentation transcript:

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory Committee 25 February 2011

Inactivated Vaccine Serology Studies l Recent A(H1N1)pdm09, A(H3N2) and B isolates were analyzed by using 12 panels of sera from adults, elderly and pediatric populations receiving seasonal trivalent inactivated vaccine ( formulation). l Sera were analyzed for the presence of antibodies to the HA antigens of recent virus isolates –Hemagglutination inhibition (HI) titers for recent isolates were compared to HI titer of the vaccine virus by HI assay –A subset of sera were tested by micro-neutralization assay 2

Serum panels used for studies: seasonal trivalent vaccine AUSTRALIAA/California/7/2009 (H1N1pdm) (NYMC X-179A) A/Victoria/210/2009 (H3N2) (NYMC X-187) B/Brisbane/60/2008 CHINA EUROPE JAPAN USA ADULTS OLDER ADULTS CHILDREN ADULTS OLDER ADULTS ADULTS OLDER ADULTS ADULTS OLDER ADULTS CHILDREN ADULTS OLDER ADULTS A/California/7/2009 (H1N1pdm) (NYMC X-179A) A/Victoria/210/2009 (H3N2) (NYMC X-187) B/Brisbane/60/2008 A/California/7/2009 (H1N1pdm) (NYMC X-181) A/Victoria/210/2009 (H3N2) (NYMC X-187) B/Brisbane/60/2008 BX-35 A/California/7/2009 (H1N1pdm) (NYMC X-179A) A/Victoria/210/2009 (H3N2) (NYMC X-187) B/Brisbane/60/2008 3

A(H1N1)pdm09 Virus 4

Antigenic cartography of A(H1N1)pdm09 isolates 5 This slide shows the antigenic map generated from HI data using ferret sera and H1N1 viruses. Viruses are represented as circles, antisera as squares. Vaccine strain are represented by the larger dot, other strains are coloured by antigenic cluster. Grid indicates 1 unit of antigenic distance, a 2- fold dilution in HI titer.

Antigens for serology: pandemic A(H1N1) 2011 VACCINE VIRUSES A/California/07/2009 (wt, X-179A and X-181) REPRESENTATIVE CURRENT VIRUSES A/Christchurch/16/2010 n125d, d94n v250a A/Kentucky/9/2010* g155e A/Milano/3/2010 (MDCK cell) A/Brisbane/10/2010 n125d A/Wisconsin/08/2010 s183p A/Sichuan/SWL-1/2009 l32i A/Shanghai-Changning/SWL1700/2010 e374k q223r A/Victoria/663/2010 A/Perth/219/2010 s185t, s451n A/Sri Lanka/21/2010 A/Brisbane/59/2007 [former seasonal A(H1N1)] 6

HI ANTIBODY RESPONSES TO THE PANDEMIC A(H1N1) COMPONENT (% GMT) relative GMT 7 This slide summarizes average geometric mean antibody titers of vaccine trials by HI test, indicating that A/California/7/09 antigen stimulated antibodies of similar titers to the vaccine and recent H1N1 viruses.

A(H3N2) Virus 8

Summary of A(H3N2) cartography A Green=Vic/208 clade 9 This slide shows the antigenic map generated from HI data using ferret sera and H3N2 viruses. Viruses are represented as circles, antisera as squares. Vaccine strains are represented by the larger dots, other strains are coloured by antigenic cluster. Grid indicates 1 unit of antigenic distance, a 2-fold dilution in HI titer.

Antigens for serology: A (H3N2) 2011 VACCINE VIRUSES A/Perth/16/2009-like (wt and X-187) REPRESENTATIVE CURRENT VIRUSES A/Rhode Island/1/2010 d53n, y94h, i230v, e280a A/Victoria/563/2010 d53n, y94h, i230v, e280a A/Perth/10/2010 d53n, y94h, i230v, e280a A/Wisconsin/13/2010 i260m, r261q, p162s A/Brisbane/11/2010 l194p A/Hong Kong/3170/2010 i260m, r261q, p162s A/Fujian-Tong’an/196/2009 A/Shanghai-Luwan/1466/2010* d53n, y94h, t212a, i230v, e280a A/Brisbane/220/2010 d53n, y94h, i230v, e280a A/Kobe/357/2010 (MDCK cell)* d53n,y94y,230v A/Okinawa/72/2010 (MDCK cell)* d53n,y94y,230v A/Yokohama/96/2010 (MDCK cell) d53n,y94y,230v 10

HI ANTIBODY RESPONSES TO THE A(H3N2) COMPONENT (% GMT) % GMT 11 This slide summarizes average geometric mean antibody titers of vaccine trials by HI test, indicating that A/Perth/16/2009-like HA antigen stimulated antibodies of similar titers to the vaccine and recent H3N2 viruses.

Influenza B Virus 12

Antigenic cartography of B/Victoria viruses (Cambridge University) B/Singapore/616/ This slide shows the antigenic map generated from HI data using ferret sera and B viruses. Viruses are represented as circles, antisera as squares. Vaccine strains are represented by the larger dots, other strains are coloured by antigenic cluster. Grid indicates 1 unit of antigenic distance, a 2-fold dilution in HI titer.

Antigenic cartography of B/Yamagata viruses (Cambridge University) 14 This slide shows the antigenic map generated from HI data using ferret sera and B viruses. Viruses are represented as circles, antisera as squares. Vaccine strains are represented by the larger dots, other strains are coloured by antigenic cluster. Grid indicates 1 unit of antigenic distance, a 2-fold dilution in HI titer.

Antigens for serology: B 2011 VACCINE VIRUS B/Brisbane/60/2008 REPRESENTATIVE CURRENT VIRUSES B/Singapore/616/2008* clade 6 B/Bolivia/1526/2010* clade 6 B/Georgia/28/2010* clade 1 B/Genoa/2/2010 B/Hunan-Yuhua/1930/2010 clade 1 B/Heilongjiang-Hulan/116/2010 clade 1 B/Victoria/506/2010 clade 1 B/Hiroshima/9/2010 (egg or cell) clade 1 B/Florida/4/2006 B/Wisconsin/1/2010 B/Hubei Wujiagang/158/2009 B/England/110/2010 B/Washington/1/2010 B/Guangdong-Luohu/1512/2010 B/Fujian Gulou/1272/

HI ANTIBODY RESPONSES TO THE B COMPONENT (% GMT) % GMT 16 This slide summarizes average geometric mean antibody titers of vaccine trials by HI test, indicating that B/Brisbine/60/2008 HA antigen stimulated antibodies of similar titers to the vaccine and recent B/Vic/2/87 lineage viruses, but titers were lower to recent B/Yamagate/16/88 lineage viruses.

Conclusions l H1N1 – Representative recent pandemic A(H1N1) viruses were covered by vaccine containing A/California/07/2009 l H3N2 – Representative recent (H3N2) viruses were covered by vaccine containing A/Perth/16/2009-like vaccines l B – B/VICTORIA/2/87-lineage Representative recent viruses were well covered by current vaccine – B/YAMAGATA/16/88-lineage Representative recent viruses were less well covered by current vaccine 17